+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Oral Biologics & Biosimilars Global Market Opportunities and Strategies to 2030

  • ID: 5170952
  • Report
  • October 2020
  • Region: Global
  • 317 Pages
  • The Business Research Company

FEATURED COMPANIES

  • 3SBio
  • AstraZeneca
  • Boehringer Ingelheim
  • Geropharm
  • Julphar
  • Novartis

'Oral Biologics & Biosimilars Global Market Opportunities and Strategies to 2030' provides the strategists, marketers and senior management with the critical information they need to assess the global oral biologics and biosimilars market.

Reasons to Purchase

  • Outperform competitors using accurate up to date demand-side dynamics information.
  • Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
  • Identify growth segments for investment.
  • Facilitate decision making on the basis of historic and forecast data and the drivers and restraints on the market.
  • Create regional and country strategies on the basis of local data and analysis.
  • Stay abreast of the latest customer and market research findings
  • Benchmark performance against key competitors.
  • Develop strategies based on likely future developments.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Gain a global perspective on the development of the market.

Description:

Where is the largest and fastest-growing market for the oral biologics and biosimilars market? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The global oral biologics and biosimilars market opportunities and strategies to 2030 report answers all these questions and many more.

The report covers the following chapters:

  • Executive Summary - The executive summary section of the report gives a brief overview and summary of the report.
  • Report Structure - This section gives the structure of the report and the information covered in the various sections.
  • Introduction - The introduction section of the report gives a brief introduction about segmentation by geography, segmentation by therapeutic mechanism, by disease, molecule type and by distribution channel.
  • Market Characteristics - The market characteristics section of the report defines and explains the oral biologics & biosimilars market. This chapter includes different services covered in the report and basic definitions.
  • Supply Chain - The supply chain section of the report defines and explains the key players in the oxygen market supply chain.
  • Product Analysis - The product analysis section of the report describes the leading products/services in the market along with key features and differentiators for those products/services.
  • Product Pipeline Analysis - This chapter gives the information on oral biologics & biosimilars product pipeline analysis.
  • Customer Information- This chapters covers recent customers’ trends/preferences in the global oxygen market.
  • Trends And Strategies - This chapter describes the major trends shaping the global oxygen market. This section highlights likely future developments in the market and suggests approaches companies can take to exploit these opportunities.
  • Impact of COVID-19 - This section describes the impact of COVID-19 on the oral biologics and biosimilars market R&D funding market.
  • Global Oral Biologics & Biosimilars Comparative Analysis Of Overall Biologics & Oral Biologics - This section describes oral biologics & biosimilars comparative analysis of overall biologics and oral biologics.
  • Global Oral Biologics & Biosimilars Rise & Evolution - This section describes oral biologics & biosimilars market rise and evolution.
  • Oral Biologics & Biosimilars Companies’ Investment In Research And Development - This section describes oral biologics & biosimilars companies’ investment in research and development
  • Major Oral Biologics & Biosimilars Developments By Disease - This section describes major oral biologics & biosimilars developments by disease.
  • Global Market Size And Growth - This section contains the global historic (2015-2019) and forecast (2023F, 2025F, 2030F) market values, and drivers and restraints that support and restrain the growth of the market in the historic and forecast periods.
  • Market Segmentation - This section contains the market values (2015-2019, 2019-2023F, 2025F, 2030F) and analysis for segment by type in the market.
  • Regional Analysis - This section contains the historic (2015-2019), forecast (2019-2023F, 2025F, 2030F) market value and growth and market share comparison by region.
  • Regional Market Size And Growth - This section contains the region’s market size (2019), historic and forecast (2015-2019, and 2023F, 2025F, 2030F) market values, and growth and market share comparison of major countries within the region. This report includes information on all the regions (Asia Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa).
  • Competitive Landscape - This section covers details on the competitive landscape of the global oral biologics & biosimilars market, estimated market shares and company profiles of the leading players.
  • Key Mergers And Acquisitions - This chapter gives the information on recent mergers and acquisitions in the market covered in the report. This section gives key financial details of mergers and acquisitions which have shaped the market in recent years.
  • Market Opportunities And Strategies- This section includes market opportunities and strategies based on findings of the research. This section also gives information on growth opportunities across countries, segments and strategies to be followed in those markets. It gives an understanding of where there is significant business to be gained by competitors in the next five years.
  • Conclusions And Recommendations - This section includes conclusions and recommendations based on the findings of the research. This section also gives recommendations for pharmaceuticals providers in terms of product offerings, geographic expansion, marketing strategies and target groups.
  • Appendix - This section includes details on the NAICS codes covered, abbreviations and currencies codes used in this report.

Markets Covered:

The global oral biologics and biosimilars market is segmented -

  • By Disease: Diabetes; Arthritis & Chron's Disease; Cancer; Infectious Diseases; Other Autoimmune Disease; Others Diseases
  • By Molecule Type: Vaccines; Proteins & Peptides; Monoclonal Antibodies; Others
  • By Therapeutic Mechanism: TNF-Alpha; Lymphocyte Modulators; Interleukin Inhibitors; GPCR; Immunostimulants; Others
  • By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies

Companies Mentioned: Merck & Co.; GlaxoSmithKline; Novo Nordisk; ALK-Abello A/S; Aimmune Therapeutics, Inc.

Countries: China, Japan, India, Australia, Indonesia, South Korea, USA, Brazil, UK, Germany, France, Russia.

Regions: Asia Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Time series: Five years historic and forecast.

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita

Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • 3SBio
  • AstraZeneca
  • Boehringer Ingelheim
  • Geropharm
  • Julphar
  • Novartis

1. Oral Biologics & Biosimilars Market Executive Summary

2. Table of Contents

3. List of Figures

4. List of Tables

5. Report Structure

6. Introduction
6.1.1. Segmentation by Geography
6.1.2. Segmentation by Disease
6.1.3. Segmentation by Molecule Type
6.1.4. Segmentation by Therapeutic Mechanism
6.1.5. Segmentation by Distribution Channel

7. Oral Biologics & Biosimilars Market Characteristics
7.1. Market Definition
7.2. Market Segmentation by Disease
7.2.1. Diabetes
7.2.2. Arthritis and Crohn’s Disease
7.2.3. Cancer
7.2.4. Infectious Disease
7.2.5. Other Autoimmune Disease
7.2.6. Other Diseases
7.3. Market Segmentation by Molecule Type
7.3.1. Vaccines
7.3.2. Monoclonal Antibodies
7.3.3. Proteins and Peptides
7.3.4. Others
7.4. Market Segmentation by Therapeutic Mechanism
7.4.1. Lymphocyte Modulators
7.4.2. Interleukin Inhibitors
7.4.3. Tumor Necrosis Factor-Alpha Inhibitors
7.4.4. Immunostimulants
7.4.5. GPCR Modulators
7.4.6. Others
7.5. Market Segmentation by Distribution Channel
7.5.1. Hospital Pharmacies
7.5.2. Retail Pharmacies
7.5.3. Online Pharmacies

8. Oral Biologics and Biosimilars Market, Supply Chain Analysis
8.1. Raw Material Suppliers
8.2. Contract Research Organization (CRO)
8.3. Oral Biologics and Biosimilars Manufacturers
8.3.1. Drug Discovery
8.3.2. Preclinical and Clinical Trials
8.3.3. Patents Upon Discovery and Approval
8.3.4. Drug Manufacturing
8.4. Contract Manufacturing Organization (CMO)
8.5. Wholesalers/Distributors
8.6. Retailers (Pharmacies) and Hospitals
8.7. End-Users

9. Oral Biologics & Biosimilars Market Product Analysis - Product Examples

10. Oral Biologics & Biosimilars Market, Product Pipeline Analysis

11. Oral Biologics and Biosimilars Market Customer Information
11.1. Knowledge of Biosimilars and Its Difference from Generic Drugs
11.2. Patients’ Perspectives Concerning Biosimilars
11.3. Policies Implemented for Pricing Biosimilar Medicines in Different Countries
11.4. Patients Ready for Cost-saving Biosimilars
11.5. Physicians’ Knowledge and Attitudes Towards Biosimilars in Russia
11.6. Oral Version of Biologics could Improve Patient Medication Adherence
11.7. Canadian Physicians are Familiar with Biosimilars but Lack Understanding

12. Oral Biologics & Biosimilars Market Trends and Strategies
12.1. Revised FDA Regulations to Facilitate Biologics Drug Development
12.2. Higher Profit Margins for Biologics
12.3. Shift from Small Molecules to Biologics
12.4. Microneedle Pills
12.5. New Insulin Biosimilars
12.6. Robust Research & Development
12.7. Large Number of Strategic Partnerships
12.8. Extensive Use in Treatment of Cancer, Diabetes and Other Autoimmune Diseases
12.9. Increase in Comfort & Compliance by Patients

13. Impact of COVID-19 on Oral Biologics and Biosimilars Market R&D Funding

14. Global Oral Biologics & Biosimilars Comparative Analysis of Overall Biologics & Oral Biologics

15. Global Oral Biologics & Biosimilars Rise & Evolution
15.1. Rise/Evolution of Oral Biologics and Biosimilars
15.2. 2006-2015
15.3. 2017- Present Day

16. Oral Biologics & Biosimilars Companies’ Investment in Research and Development
16.1. Catalent Invested $214 Million to Improve Biologics and Oral Delivery Capabilities
16.2. TrueNorth Invested INR 536 Crore in Biocon Biologics
16.3. Fujifilm to Invest $928 Million to Expand Its Danish Biologics Production Facility

17. Major Oral Biologics & Biosimilars Developments by Disease
17.1. Diabetes
17.2. Cancer
17.3. Arthritis
17.4. Gastro Intestinal Disorders
17.5. Allergic Reactions

18. Global Oral Biologics & Biosimilars Market Size and Growth
18.1. Market Size
18.2. Historic Market Growth, 2015 - 2019, Value ($ Million)
18.2.1. Drivers of the Market 2015 - 2019
18.2.2. Restraints on the Market 2015-19
18.3. Forecast Market Growth, 2019 - 2023, 2025F, 2030F Value ($ Million)
18.3.1. Drivers of the Market 2019 - 2023
18.3.2. Restraints of the Market 2019-2023

19. Global Oral Biologics & Biosimilars Market Segmentation
19.1. Global Oral Biologics & Biosimilars Market, Segmentation by Disease, Historic and Forecast, 2015 - 2019, 2023F, 2025F, 2030F, Value ($ Million)
19.1.1. Infectious Diseases
19.1.2. Diabetes
19.1.3. Other Autoimmune Diseases
19.1.4. Others
19.1.5. Cancer
19.1.6. Arthritis & Chron's Disease
19.2. Global Oral Biologics & Biosimilars Market, Segmentation by Molecule Type, Historic and Forecast, 2015 - 2019, 2023F, 2025F, 2030F, Value ($ Million)
19.2.1. Vaccines
19.2.2. Proteins & Peptides
19.2.3. Others
19.2.4. mAbs
19.3. Global Oral Biologics & Biosimilars Market, Segmentation by Therapeutic Mechanism Type, Historic and Forecast, 2015 - 2019, 2023F, 2025F, 2030F, Value ($ Million)
19.3.1. Immunostimulants
19.3.2. Others (Interferons, Opioid receptors, Calcitonin receptor etc)
19.3.3. GPCR (Insulin, Growth Hormone, Parathyroid Hormone)
19.3.4. TNF-Alpha
19.3.5. Lymphocyte Modulators
19.3.6. Interleukin Inhibitors
19.4. Global Oral Biologics & Biosimilars Market, Segmentation by Distribution Channel, Historic and Forecast, 2015 - 2019, 2023F, 2025F, 2030F, Value ($ Million)
19.4.1. Hospital Pharmacies
19.4.2. Retail Pharmacies
19.4.3. Online Pharmacies

20. Oral Biologics & Biosimilars Market, Regional and Country Analysis
20.1. Global Oral Biologics & Biosimilars Market, by Region, Historic and Forecast, 2015 - 2019, 2023F, 2025F, 2030F, Value ($ Million)
20.2. Global Oral Biologics & Biosimilars Market, by Country, Historic and Forecast, 2015 - 2019, 2023F, 2025F, 2030F, Value ($ Million)

21. Asia-Pacific Oral Biologics & Biosimilars Market
21.1. Asia-Pacific Oral Biologics & Biosimilars Market Overview
21.1.1. Region Information
21.1.2. Market Information
21.1.3. Background Information
21.1.4. Government Initiatives
21.1.5. Regulations
21.1.6. Regulatory Bodies
21.1.7. Major Associations
21.1.8. Taxes Levied
21.1.9. Corporate Tax Structure
21.1.10. Investments
21.1.11. Major Companies
21.2. Asia-Pacific Oral Biologics & Biosimilars Market, Historic Market Growth, 2015 - 2019, Value ($ Million)
21.3. Asia-Pacific Oral Biologics & Biosimilars Market, Forecast Market Growth, 2019 - 2023, 2025F, 2030F Value ($ Million)
21.4. Asia-Pacific Oral Biologics & Biosimilars Market, Segmentation by Disease, Historic and Forecast, 2015 - 2019, 2023F, 2025F, 2030F, Value ($ Million)
21.5. Asia-Pacific Oral Biologics & Biosimilars Market: Country Analysis
21.6. China Oral Biologics & Biosimilars Market
21.7. China Oral Biologics & Biosimilars Market Overview
21.7.1. Country Information
21.7.2. Market Information
21.7.3. Background Information
21.7.4. Government Initiatives
21.7.5. Regulations
21.7.6. Regulatory Bodies
21.7.7. Major Associations
21.7.8. Taxes Levied
21.7.9. Corporate Tax Structure
21.7.10. Investments
21.7.11. Major Companies
21.8. China Oral Biologics & Biosimilars Market, Historic Market Growth, 2015 - 2019, Value ($ Million)
21.9. China Oral Biologics & Biosimilars Market, Forecast Market Growth, 2019 - 2023, 2025F, 2030F Value ($ Million)
21.10. China Oral Biologics & Biosimilars Market, Segmentation by Disease, Historic and Forecast, 2015 - 2019, 2023F, 2025F, 2030F, Value ($ Million)
21.11. India Oral Biologics & Biosimilars Market
21.12. India Oral Biologics & Biosimilars Market Overview
21.12.1. Country Information
21.12.2. Market Information
21.12.3. Background Information
21.12.4. Government Initiatives
21.12.5. Regulations
21.12.6. Regulatory Bodies
21.12.7. Major Associations
21.12.8. Taxes Levied
21.12.9. Corporate Tax Structure
21.12.10. Investments
21.12.11. Major Companies
21.13. India Oral Biologics & Biosimilars Market, Historic Market Growth, 2015 - 2019, Value ($ Million)
21.14. India Oral Biologics & Biosimilars Market, Forecast Market Growth, 2019 - 2023, 2025F, 2030F Value ($ Million)
21.15. India Oral Biologics & Biosimilars Market, Segmentation by Disease, Historic and Forecast, 2015 - 2019, 2023F, 2025F, 2030F, Value ($ Million)
21.16. Japan Oral Biologics & Biosimilars Market
21.17. Japan Oral Biologics & Biosimilars Market Overview
21.17.1. Country Information
21.17.2. Market Information
21.17.3. Background Information
21.17.4. Government Initiatives
21.17.5. Regulations
21.17.6. Regulatory Bodies
21.17.7. Major Associations
21.17.8. Taxes Levied
21.17.9. Corporate Tax Structure
21.17.10. Investments
21.17.11. Major Companies
21.18. Japan Oral Biologics & Biosimilars Market, Historic Market Growth, 2015 - 2019, Value ($ Million)
21.19. Japan Oral Biologics & Biosimilars Market, Forecast Market Growth, 2019 - 2023, 2025F, 2030F Value ($ Million)
21.20. Japan Oral Biologics & Biosimilars Market, Segmentation by Disease, Historic and Forecast, 2015 - 2019, 2023F, 2025F, 2030F, Value ($ Million)
21.21. Australia Oral Biologics & Biosimilars Market
21.22. Australia Oral Biologics & Biosimilars Market, Historic Market Growth, 2015 - 2019, Value ($ Million)
21.23. Australia Oral Biologics & Biosimilars Market, Forecast Market Growth, 2019 - 2023, 2025F, 2030F Value ($ Million)
21.24. Australia Oral Biologics & Biosimilars Market, Segmentation by Disease, Historic and Forecast, 2015 - 2019, 2023F, 2025F, 2030F, Value ($ Million)
21.25. Indonesia Oral Biologics & Biosimilars Market
21.26. Indonesia Oral Biologics & Biosimilars Market, Historic Market Growth, 2015 - 2019, Value ($ Million)
21.27. Indonesia Oral Biologics & Biosimilars Market, Forecast Market Growth, 2019 - 2023, 2025F, 2030F Value ($ Million)
21.28. Indonesia Oral Biologics & Biosimilars Market, Segmentation by Disease, Historic and Forecast, 2015 - 2019, 2023F, 2025F, 2030F, Value ($ Million)
21.29. South Korea Oral Biologics & Biosimilars Market
21.30. South Korea Oral Biologics & Biosimilars Market, Historic Market Growth, 2015 - 2019, Value ($ Million)
21.31. South Korea Oral Biologics & Biosimilars Market, Forecast Market Growth, 2019 - 2023, 2025F, 2030F Value ($ Million)
21.32. South Korea Oral Biologics & Biosimilars Market, Segmentation by Disease, Historic and Forecast, 2015 - 2019, 2023F, 2025F, 2030F, Value ($ Million)

22. Western Europe Oral Biologics & Biosimilars Market
22.1. Western Europe Oral Biologics & Biosimilars Market Overview
22.1.1. Region Information
22.1.2. Market Information
22.1.3. Background Information
22.1.4. Government Initiatives
22.1.5. Regulations
22.1.6. Regulatory Bodies
22.1.7. Major Associations
22.1.8. Taxes Levied
22.1.9. Corporate Tax Structure
22.1.10. Investments
22.1.11. Major Companies
22.2. Western Europe Oral Biologics & Biosimilars Market, Historic Market Growth, 2015 - 2019, Value ($ Million)
22.3. Western Europe Oral Biologics & Biosimilars Market, Forecast Market Growth, 2019 - 2023, 2025F, 2030F Value ($ Million)
22.4. Western Europe Oral Biologics & Biosimilars Market, Segmentation by Disease, Historic and Forecast, 2015 - 2019, 2023F, 2025F, 2030F, Value ($ Million)
22.5. Western Europe Oral Biologics & Biosimilars Market: Country Analysis
22.6. UK Oral Biologics & Biosimilars Market
22.7. UK Oral Biologics & Biosimilars Market Overview
22.7.1. Country Information
22.7.2. Market Information
22.7.3. Background Information
22.7.4. Government Initiatives
22.7.5. Regulations
22.7.6. Regulatory Bodies
22.7.7. Major Associations
22.7.8. Taxes Levied
22.7.9. Corporate Tax Structure
22.7.10. Investments
22.7.11. Major Companies
22.8. UK Oral Biologics & Biosimilars Market, Historic Market Growth, 2015 - 2019, Value ($ Million)
22.9. UK Oral Biologics & Biosimilars Market, Forecast Market Growth, 2019 - 2023, 2025F, 2030F Value ($ Million)
22.10. UK Oral Biologics & Biosimilars Market, Segmentation by Disease, Historic and Forecast, 2015 - 2019, 2023F, 2025F, 2030F, Value ($ Million)
22.11. Germany Oral Biologics & Biosimilars Market
22.12. Germany Oral Biologics & Biosimilars Market, Historic Market Growth, 2015 - 2019, Value ($ Million)
22.13. Germany Oral Biologics & Biosimilars Market, Forecast Market Growth, 2019 - 2023, 2025F, 2030F Value ($ Million)
22.14. Germany Oral Biologics & Biosimilars Market, Segmentation by Disease, Historic and Forecast, 2015 - 2019, 2023F, 2025F, 2030F, Value ($ Million)
22.15. France Oral Biologics & Biosimilars Market
22.16. France Oral Biologics & Biosimilars Market, Historic Market Growth, 2015 - 2019, Value ($ Million)
22.17. France Oral Biologics & Biosimilars Market, Forecast Market Growth, 2019 - 2023, 2025F, 2030F Value ($ Million)
22.18. France Oral Biologics & Biosimilars Market, Segmentation by Disease, Historic and Forecast, 2015 - 2019, 2023F, 2025F, 2030F, Value ($ Million)

23. Eastern Europe Oral Biologics & Biosimilars Market
23.1. Eastern Europe Oral Biologics & Biosimilars Market Overview
23.1.1. Region Information
23.1.2. Market Information
23.1.3. Background Information
23.1.4. Government Initiatives
23.1.5. Regulations
23.1.6. Regulatory Bodies
23.1.7. Major Associations
23.1.8. Investments
23.1.9. Taxes Levied
23.1.10. Corporate Tax Structure
23.1.11. Major Companies
23.2. Eastern Europe Oral Biologics & Biosimilars Market, Historic Market Growth, 2015 - 2019, Value ($ Million)
23.3. Eastern Europe Oral Biologics & Biosimilars Market, Forecast Market Growth, 2019 - 2023, 2025F, 2030F Value ($ Million)
23.4. Eastern Europe Oral Biologics & Biosimilars Market, Segmentation by Disease, Historic and Forecast, 2015 - 2019, 2023F, 2025F, 2030F, Value ($ Million)
23.5. Eastern Europe Oral Biologics & Biosimilars Market: Country Analysis
23.6. Russia Oral Biologics & Biosimilars Market
23.7. Russia Oral Biologics & Biosimilars Market, Historic Market Growth, 2015 - 2019, Value ($ Million)
23.8. Russia Oral Biologics & Biosimilars Market, Forecast Market Growth, 2019 - 2023, 2025F, 2030F Value ($ Million)
23.9. Russia Oral Biologics & Biosimilars Market, Segmentation by Disease, Historic and Forecast, 2015 - 2019, 2023F, 2025F, 2030F, Value ($ Million)

24. North America Oral Biologics & Biosimilars Market
24.1. North America Oral Biologics & Biosimilars Market Overview
24.1.1. Region Information
24.1.2. Market Information
24.1.3. Background Information
24.1.4. Government Initiatives
24.1.5. Regulations
24.1.6. Regulatory Bodies
24.1.7. Major Associations
24.1.8. Taxes Levied
24.1.9. Corporate Tax Structure
24.1.10. Investments
24.1.11. Major Companies
24.2. North America Oral Biologics & Biosimilars Market, Historic Market Growth, 2015 - 2019, Value ($ Million)
24.3. North America Oral Biologics & Biosimilars Market, Forecast Market Growth, 2019 - 2023, 2025F, 2030F Value ($ Million)
24.4. North America Oral Biologics & Biosimilars Market, Segmentation by Disease, Historic and Forecast, 2015 - 2019, 2023F, 2025F, 2030F, Value ($ Million)
24.5. North America Oral Biologics & Biosimilars Market: Country Analysis
24.6. USA Oral Biologics & Biosimilars Market
24.7. USA Oral Biologics & Biosimilars Market Overview
24.7.1. Country Information
24.7.2. Market Information
24.7.3. Background Information
24.7.4. Government Initiatives
24.7.5. Regulations
24.7.6. Regulatory Bodies
24.7.7. Major Associations
24.7.8. Tax Levied
24.7.9. Corporate Tax Structure
24.7.10. Investments
24.7.11. Major Companies
24.8. USA Oral Biologics & Biosimilars Market, Historic Market Growth, 2015 - 2019, Value ($ Million)
24.9. USA Oral Biologics & Biosimilars Market, Forecast Market Growth, 2019 - 2023, 2025F, 2030F Value ($ Million)
24.10. USA Oral Biologics & Biosimilars Market, Segmentation by Disease, Historic and Forecast, 2015 - 2019, 2023F, 2025F, 2030F, Value ($ Million)

25. South America Oral Biologics & Biosimilars Market
25.1. South America Oral Biologics & Biosimilars Market Overview
25.1.1. Region Information
25.1.2. Market Information
25.1.3. Background Information
25.1.4. Government Initiatives
25.1.5. Regulations
25.1.6. Regulatory Bodies
25.1.7. Major Associations
25.1.8. Taxes Levied
25.1.9. Corporate Tax Structure
25.1.10. Investments
25.1.11. Major Companies
25.2. South America Oral Biologics & Biosimilars Market, Historic Market Growth, 2015 - 2019, Value ($ Million)
25.3. South America Oral Biologics & Biosimilars Market, Forecast Market Growth, 2019 - 2023, 2025F, 2030F Value ($ Million)
25.4. South America Oral Biologics & Biosimilars Market, Segmentation by Disease, Historic and Forecast, 2015 - 2019, 2023F, 2025F, 2030F, Value ($ Million)
25.5. South America Oral Biologics & Biosimilars Market: Country Analysis
25.6. Brazil Oral Biologics & Biosimilars Market
25.7. Brazil Oral Biologics & Biosimilars Market, Historic Market Growth, 2015 - 2019, Value ($ Million)
25.8. Brazil Oral Biologics & Biosimilars Market, Forecast Market Growth, 2019 - 2023, 2025F, 2030F Value ($ Million)
25.9. Brazil Oral Biologics & Biosimilars Market, Segmentation by Disease, Historic and Forecast, 2015 - 2019, 2023F, 2025F, 2030F, Value ($ Million)

26. Middle East Oral Biologics & Biosimilars Market
26.1. Middle East Oral Biologics & Biosimilars Market Overview
26.1.1. Region Information
26.1.2. Market Information
26.1.3. Background Information
26.1.4. Government Initiatives
26.1.5. Regulations
26.1.6. Regulatory Bodies
26.1.7. Major Associations
26.1.8. Taxes Levied
26.1.9. Corporate Tax Structure
26.1.10. Investments
26.1.11. Major Companies
26.2. Middle East Oral Biologics & Biosimilars Market, Historic Market Growth, 2015 - 2019, Value ($ Million)
26.3. Middle East Oral Biologics & Biosimilars Market, Forecast Market Growth, 2019 - 2023, 2025F, 2030F Value ($ Million)
26.4. Middle East Oral Biologics & Biosimilars Market, Segmentation by Disease, Historic and Forecast, 2015 - 2019, 2023F, 2025F, 2030F, Value ($ Million)

27. Africa Oral Biologics & Biosimilars Market
27.1. Africa Oral Biologics & Biosimilars Market Overview
27.1.1. Region Information
27.1.2. Market Information
27.1.3. Background Information
27.1.4. Regulations
27.1.5. Regulatory Bodies
27.1.6. Major Associations
27.1.7. Taxes Levied
27.1.8. Corporate Tax Structure
27.1.9. Investments
27.1.10. Major Companies
27.2. Africa Oral Biologics & Biosimilars Market, Historic Market Growth, 2015 - 2019, Value ($ Million)
27.3. Africa Oral Biologics & Biosimilars Market, Forecast Market Growth, 2019 - 2023, 2025F, 2030F Value ($ Million)
27.4. Africa Oral Biologics & Biosimilars Market, Segmentation by Disease, Historic and Forecast, 2015 - 2019, 2023F, 2025F, 2030F, Value ($ Million)

28. Global Oral Biologics & Biosimilars Market Competitive Landscape
28.1. Company Profiles
28.2. Merck & Co.
28.2.1. Company Overview
28.2.2. Products and Services
28.2.3. Business Strategy
28.2.4. Financial Overview
28.3. GlaxoSmithKline
28.3.1. Company Overview
28.3.2. Products and Services
28.3.3. Financial Overview
28.4. Novo Nordisk
28.4.1. Company Overview
28.4.2. Products and Services
28.4.3. Business Strategy
28.4.4. Financial Overview
28.5. ALK-Abello A/S
28.5.1. Company Overview
28.5.2. Products and Services
28.5.3. Business Strategy
28.5.4. Financial Overview
28.6. Aimmune Therapeutics, Inc.
28.6.1. Company Overview
28.6.2. Products and Services
28.6.3. Business Strategy
28.6.4. Financial Overview

29. Key Mergers and Acquisitions in the Oral Biologics & Biosimilars Market
29.1. Abbvie Acquired Allergan
29.2. Takeda Pharmaceutical Company Acquired PvP Biologics, Inc.
29.3. True North Acquired Stake in Biocon Biologics
29.4. Catalent, Inc. Acquired Bristol Myers Squibb’s Oral Dose Manufacturing Facility
29.5. Amgen Acquired Psoriasis Drug Otezla from Celgene
29.6. Amgen’s Acquisition of Otezla from Celgene
29.7. Bristol Myers Acquired Celgene
29.8. Biocon Acquires Pfizer's R&D Facility to Boost Biosimilars Development
29.9. Biocon Biologics Acquired R&D Facility from Pfizer Healthcare India
29.10. AstraZeneca Strikes Stock Deal with Daiichi Sankyo
29.11. Takeda Pharmaceutical Company Acquires Shire
29.12. Kashiv Pharma Acquired Adello Biologics
29.13. Stada Acquired Majority Stake in Bioceuticals
29.14. Catalent, Inc. Acquired Cook Pharmica LLC

30. Oral Biologics & Biosimilars Market Opportunities and Strategies
30.1. Global Oral Biologics & Biosimilars Market in 2023 - Countries Offering most New Opportunities
30.2. Global Oral Biologics & Biosimilars Market in 2023 - Segments Offering most New Opportunities
30.3. Global Oral Biologics & Biosimilars Market in 2023 - Growth Strategies
30.3.1. Market Trend Based Strategies
30.3.2. Competitor Strategies

31. Oral Biologics & Biosimilars Market, Conclusions and Recommendations
31.1. Conclusions
31.1.1. Product
31.1.2. Place
31.1.3. Price
31.1.4. Promotion

32. Appendix
32.1. Market Data Sources
32.2. Research Methodology
32.3. Currencies
32.4. Research Inquiries
32.5. About the Publisher
32.6. Copyright and Disclaimer

Note: Product cover images may vary from those shown

Loading
LOADING...

FEATURED COMPANIES

  • 3SBio
  • AstraZeneca
  • Boehringer Ingelheim
  • Geropharm
  • Julphar
  • Novartis

This report describes and evaluates the global oral biologics and biosimilars market. The oral biologics and biosimilars market consists of sales of oral biologics and biosimilars products used to treat chronic diseases such as diabetes, arthritis, and cancer. It covers 2015 to 2019, termed the historic period, and 2019 to 2023 termed the forecast period, along with further forecasts for the periods 2023-2025 and 2025-2030.

The global oral biologics and biosimilars market reached a value of nearly $3,076.1 million in 2019, having grown at a compound annual growth rate (CAGR) of 6.5% since 2015, and is expected to grow at a CAGR of 17.1% to nearly $5,787.9 million by 2023. Also, the market is expected to grow to $8,687.7 million in 2025 at a CAGR of 22.5% and to $23,585.5 million in 2030 at a CAGR of 22.1%.

Growth in the historic period resulted from increased collaboration and partnerships between market players for better insights, increased need for immunology, increased demand due to the cost-effective manufacturing process, aging population, government initiatives, and the ability to command high prices. Factors that negatively affected growth in the historic period were lack of awareness on biosimilars among primary care physicians and specialists, difficulty in manufacturing biologics and pricing pressures from regulators.

Going forward, robust research and development activities for the development of oral biologics, lean towards pills over injections, adoption of unhealthy lifestyles, technological advances, ease of use of oral biologics, increase in healthcare access, reimbursement of biologics, rise in biosimilars, and rising prevalence of chronic diseases are expected to drive the market. Higher supervision during clinical studies and stringent regulations related to biosimilar approvals, prolonged production and approval time, difficulties in pricing, nomenclature challenges are major factors that could hinder the growth of the oral biologics and biosimilars market in the future.

The oral biologics and biosimilars market is segmented by therapeutic mechanism into TNF-alpha, lymphocyte modulators, interleukin inhibitors, GPCR (insulin, growth hormone, parathyroid hormone), immunostimulants, and others (Interferons, Opioid receptors, Calcitonin receptor etc). The others (Interferons, Opioid receptors, Calcitonin receptor etc) was the largest segment of the oral biologics and biosimilars market by therapeutic mechanism, accounting for $676.1 million of the total market in 2019.

The oral biologics and biosimilars market is segmented by disease into diabetes, arthritis & chron's disease, cancer, infectious diseases, other autoimmune diseases, other diseases. The infectious diseases were the largest segment of the oral biologics and biosimilars market by disease, accounting for $2,305.6 million or 74.9% of the total market in 2019 and this market is expected to grow at a CAGR of 7.1% during 2019-2023. The diabetes market is expected to be the fastest-growing segment going forward at a CAGR of 82.6%.

The oral biologics and biosimilars market is segmented by molecule type into vaccines, proteins & peptides, mAbs and others. The vaccines were the largest segment of the oral biologics and biosimilars market by molecule type, accounting for $2,305.6 million or 74.9% of the total market in 2019 and this market is expected to grow at a CAGR of 7.1% during 2019-2023. The proteins & peptides market is expected to be the fastest-growing segment going forward at a CAGR of 38.0%.
The oral biologics and biosimilars market is segmented by distribution channel into hospital pharmacies, retail pharmacies and online pharmacies. The hospital pharmacies were the largest segment of the oral biologics and biosimilars market by distribution channel, accounting for $1,891.3 million or 61.5% of the total market in 2019 and this market is expected to grow at a CAGR of 18.0% during 2019-2023. The online pharmacies market is expected to be the fastest-growing segment going forward at a CAGR of 25.0%.

North America was the largest region in the oral biologics and biosimilars market, accounting for 46.2% of the global market in 2019. It was followed by Asia Pacific, Western Europe and the other regions. Going forward, the fastest growing regions in the oral biologics and biosimilars market will be Western Europe and North America, where growth will be at CAGRs of 20.3% and 18.9% respectively from 2019-2023.

The oral biologics and biosimilars market is concentrated, with a small number of large players. The top eight competitors in the market made up to 69% of the total market in 2019. Major players in the market include Merck & Co., Inc., GlaxoSmithKline, Novo Nordisk, ALK-Abelló, Aimmune Therapeutics, Inc., VIVUS, Inc, Materia Medica Holding and VECTOR-MEDICA (Russia)

The top growth potential in the oral biologics and biosimilars market by therapeutic mechanism will arise in Others (Interferons, Opioid receptors, Calcitonin receptor etc) market, which will gain $1,606.8 million of global annual sales by 2023. Vaccines and insulin products will drive the growth of these market segments. The top growth potential in the oral biologics and biosimilars market by the disease will arise in the diabetes market, which will gain $1,865.5 million of global annual sales by 2030. By molecule type, Proteins & Peptides will have high market share and potential with annual sales of $15804, by 2030. The top growth potential in the oral biologics and biosimilars market by distribution channel will arise in the hospital pharmacies market, which will gain $1,770.9 million of global annual sales by 2030.

The oral biologics and biosimilars market size will gain the most in the USA at $1,423.2 million. Market-trend-based strategies for the oral biologics and biosimilars market include investing in the oral biologics market to benefit from potentially strong profit margins, shift to biologics, as the innovation rate is increasing in that field, develop microneedle injectors-based drugs to increase the bioavailability and eliminate side effects of the subcutaneous route. Player-adopted strategies in the oral biologics and biosimilars industry include strengthening oral biologics business with strategic collaborations, and through new launches and approvals, developing and commercializing new therapies for the treatment of patients with food allergies.

To take advantage of the opportunities, the publisher recommends the oral biologics and biosimilars companies to focus on strategic alliances for research & development, focus on expanding through collaborations, expand in emerging markets, consider providing biologics at a considerably lower price and manufacturers should create awareness regarding the benefits and cost-effectiveness of biosimilars.

Note: Product cover images may vary from those shown
  • 3SBio
  • Abbvie
  • Ache
  • AGC Biologics
  • Allena Pharmaceuticals
  • Altis Biologics
  • AstraZeneca
  • Bayer
  • Beijing ShuangLu Pharmaceuticals
  • Bio-Thera
  • Biocon
  • Biogen Inc.
  • BiosanaPharma
  • Boehringer Ingelheim
  • Dr Reddys
  • Eli Lilly and Company
  • Emisphere Technologies, Inc
  • Entera Bio
  • Enteris BioPharma
  • Eurofarma
  • Geropharm
  • Henlius
  • Hikma Pharmaceuticals
  • Hisun Pharma
  • Innovent Biologics
  • Johnson & Johnson
  • Julphar
  • Kyowa Hakko Kirin
  • Microgen
  • Mitsubishi Tanabe
  • Mylan
  • NovaMedica
  • Novartis
  • Oramed Pharmaceuticals
  • Qilu Pharmaceutical
  • Rani Therapeutics
  • Roche
  • Sanofi
  • Shanghai Fosun Pharmaceuticals
  • SynBio
  • Takeda
  • Valenta
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll